Propranolol, immunotherpy, and chemotherapy for small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of a blood pressure medicine (propranolol), an immunotherapy drug (adebrelimab), and standard chemotherapy for patients with extensive-stage small cell lung cancer. The goal is to see if this combo helps control the cancer better than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have extensive-stage small cell lung cancer (spread beyond the lung) or a very early stage that cannot be treated with local therapy.
- You have not received any systemic therapy (like chemotherapy or immunotherapy) for advanced disease before.
- You are generally in good health, able to care for yourself (ECOG 0-1), and have a life expectancy of at least 12 weeks.
- You can have at least one measurable tumor that can be seen on scans.
- You have acceptable organ function, such as adequate blood counts, liver and kidney function, and heart function (LVEF ≥50%).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving standard chemotherapy and radiation together with two types of immunotherapy (which helps your immune system fight cancer) for limited-stage small cell lung cancer. The goal is to see if adding these immune treatments improves outcomes compared to standard care.
This trial tests adding a drug called adebrelimab (a type of immunotherapy) before surgery for people with early-stage small cell lung cancer that can be removed. The goal is to see if it helps shrink the tumor and improve outcomes.
This trial tests a combination of the targeted drug bemotuzumab, chemotherapy, and anlotinib (which blocks blood vessel growth) followed by radiation therapy for people with extensive-stage small cell lung cancer who haven't had treatment yet. The goal is to see if this approach helps control the cancer.
This study follows patients with small cell lung cancer who receive radiation therapy combined with other treatments. Researchers will track how well the treatment works and how patients respond over time to help improve future care.
This trial tests a combination of two immunotherapy drugs (sintilimab and tafolecimab) plus standard chemotherapy as a first treatment for extensive-stage small cell lung cancer. The goal is to see if adding these drugs helps people live longer and have better outcomes.
This trial combines radiation therapy with chemotherapy and an immunotherapy drug to treat limited-stage small cell lung cancer. The goal is to see if this approach helps people live longer and delays the cancer from coming back.
Hear when a new Small Cell Lung Cancer (SCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.